Related Experiment Video
Updated: Sep 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Is immunotherapy safe and effective in patients with VEXAS syndrome?
Chiara Marvisi1,2, Francesco Muratore1,2, Vincenza Ylenia Cusenza1
1Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
None:
The use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further, there is a lack of data about their role in controlling the UBA1 clones. In this clinical case, we report a successful use of cemiplimab in a patient with VEXAS syndrome and a concomitant diagnosis of metastatic squamous cell carcinoma.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Vaccinations
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

